LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

AstraZeneca boss Pascal Soriot (pictured)) threw his weight behind its Chinese business despite the recent arrest of its boss ...

AstraZeneca, the London-listed pharmaceutical company, has put its planned £650 million investment in UK vaccine research and ...

AstraZeneca chief Pascal Soriot has said a deepening criminal probe into his company’s Chinese business is being taken “very ...

AstraZeneca's £450 million investment plan for vaccine R&D in the UK is under review as discussions on governmental ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

Platelets are cells that help your blood clot, and it was so unusual to see blood clots combined with low platelet levels, that experts coined a new medical term: vaccine-induced thrombosis with ...

London-listed drugmaker AstraZeneca said its plan to invest 650 million pounds ($833.2 million) in Britain for vaccine ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The decision by the regional board will likely give ammunition to vaccine-sceptics and anti-vaxxers who pushed against the ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...